Home' Australian Pharmacist : Australian Pharmacist March 2016 Contents Before prescribing please review Product Information available
via www.aspenpharma.com.au/products or call 1300 659 646
Minimum Product Information – Imigran (sumatriptan) 10 mg and 20 mg nasal spray, Imigran (sumatriptan succinate) 50 mg and 100 mg tablets, 50 mg and 100 mg
FDT tablets, 6 mg MK II injection. Indications: Acute relief of migraine attacks with or without aura. Injection also indicated for the acute treatment of cluster headaches.
Contraindications: Hypersensitivity to any component of the preparation; history of myocardial infarction; peripheral vascular disease or symptoms or signs consistent with IHD;
Prinzmetal’s angina/coronary vasospasm; uncontrolled hypertension; cerebrovascular accident or transient ischaemic attack; severe hepatic impairment (see full PI). Precautions:
Use only in clear diagnosis of migraine; not indicated in hemiplegic, basilar or ophthalmoplegic migraine; hypersensitivity to sulphonamides; renal and hepatic impairment;
drowsiness may occur as a result of migraine; use of nasal spray in asthmatics; medication overuse headache; not for use in patients whose risk factors suggest potential
unrecognised coronary artery or cardiovascular disease; care should be taken to exclude other potentially serious neurological conditions; patients with a history of seizures or
other risk factors which lower the seizure threshold; pregnancy (category B3); breastfeeding within 24 hours of dose; not recommended in children < 12 years and adults
> 65 years (see full PI). Interactions: Concomitant administration of any triptan/5-HT1 agonist, MAOIs, ergotamine and derivatives of ergotamine not recommended; serotonin
syndrome reported following concomitant treatment with SSRIs and SNRIs; St John’s Wort. Adverse Effects: Injection: transient pain, stinging/burning, swelling, bruising and
bleeding; other formulations: pain, tingling, heat/cold, heaviness, pressure, tightness, flushing, dizziness, weakness, fatigue, drowsiness, sensory disturbances, nausea and
vomiting, increase in blood pressure, dyspnoea. Dosage and Administration: Initiate treatment at the first sign of a migraine headache or associated symptoms. Injection: for
cluster headache or migraine, a single 6 mg dose administered via subcutaneous route, maximum 12 mg (2 doses) in 24 hours. Tablets: 50 mg–100 mg swallowed whole with
water, adjusted according to the individual’s response. Maximum of 300 mg in 24 hours. Nasal spray – adults: 20 mg administered into one nostril. For some patients 10 mg may
be effective. Adolescents (12–17 years): 10 mg-20 mg administered into one nostril with consideration given to the patient’s body weight and variability of migraine attacks.
Maximum of 40 mg in 24 hours (see full PI). (PI last amended 14/01/2014) | References: 1. IMIGRAN Approved Product Information (last amended 14/01/2014). 2. Stark C,
et al. Medicine Today volume 11, number 4:16-24. 3. Zagami, et al. MJA 2012;196:178-183. | All sales and marketing requests to: Aspen Pharmacare Australia Pty Ltd,
34-36 Chandos Street, St Leonards NSW 2065 Tel. +61 2 8436 8300 | www.aspenpharma.com.au | email@example.com | Prepared: Oct 2015.
PBS information: Authority required (STREAMLINED). Migraine attack in a
patient where attacks in the past have usually failed to respond to analgesics.
Refer to PBS Schedule for full authority information. Imigran injection is not listed on the PBS.
affects up to
18% of women
and 6% of men2
migraine, is the most
problem with which
patients present to
GPs and neurologists3
Relieving the pain:
Proven and effective migraine relief 1
Realising the choices:
IMIGRAN available in 4 formulations1
A division of
Aspen Australia comprises Aspen Asia Pacific Pty Ltd (ABN 75 146 444 484) and its subsidiaries, including Aspen
Pharmacare Australia Pty Ltd (ABN 51 096 236 985), Aspen Pharma Pty Ltd (ABN 88 004 118 594), Aspen Nutritionals
Australia Pty Limited (ACN 160 607 509), Orphan Holdings Pty Ltd (ABN 50 115 816 209), Orphan Australia Pty Ltd
(ABN 11 067 189 342) and Aspen Products Pty Ltd (ABN 17 003 144 170).
18/02/2016 2:58 PM
Links Archive Australian Pharmacist February 2016 Australian Pharmacist April 2016 Navigation Previous Page Next Page